Design of oncology clinical trials: A review

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 1, 2013, Pages 144-153

  Ananthakrishnan, Revathi ^a   Menon, Sandeep ^a  

^a NONE   (United States)

Author keywords

II and III oncology clinical trials; Phases I; PK PD modeling; Safety and efficacy endpoints; Statistical analyses; Trial designs

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; NILOTINIB; TRASTUZUMAB;

ANALYTIC METHOD; BAYES THEOREM; BREAST CANCER; CANCER PATIENT; CLINICAL STUDY; CONTINUAL REASSESSMENT METHOD; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METHODOLOGY; ONCOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

II AND III ONCOLOGY CLINICAL TRIALS; PHASES I; PK/PD MODELING; SAFETY AND EFFICACY ENDPOINTS; STATISTICAL ANALYSES; TRIAL DESIGNS;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOPLASMS; RESEARCH DESIGN;

EID: 84884160745     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.03.007     Document Type: Review

References (42)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(January (1)):57-70. [Review].
2. Jemal A., Center M.M., DeSantis C., et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology, Biomarkers and Prevention 2010, 19(August (8)):1893-1907.
3. Bray F., Jemal A., Grey N., et al. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncology 2012, 13(August (8)):790-801.
4. Awada A., Dirix L., Manso Sanchez L., et al. Staroslawska Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Annals of Oncology 2013, 24(January (1)):109-116.
5. Verma S., Miles D., Gianni L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine 2012, (October). [Epub ahead of print].
6. LoRusso P.M., Weiss D., Guardino E., et al. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clinical Cancer Research 2011, 17(October (20)):6437-6447. [Review].
7. Burris H.A. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opinion on Biological Therapy 2011, 11(June (6)):807-819.
8. Arrondeau J., Gan H.K., Razak A.R., et al. Development of anti-cancer drugs. Discovery Medicine 2010, 10(October (53)):355-362. [Review].
9. Thall P.F. A review of phase 2-3 clinical trial designs. Lifetime Data Analysis 2008, 14(March (1)):37-53. [Epub Review 2007 September 2].
10. Bretz F., Schmidli H., König F., et al. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biometrical Journal 2006, 48(August (4)):623-634.
11. Schmidli H., Bretz F., Racine A., et al. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations. Biometrical Journal 2006, 48(August (4)):635-643.
12. Gelmon K.A., Eisenhauer E.A., Harris A.L., et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?. Journal of the National Cancer Institute 1999, 91(August (15)):1281-1287. [Review].
13. Le Tourneau C., Lee J.J., Siu L.L. Dose escalation methods in phase I cancer clinical trials. Journal of the National Cancer Institute 2009, 101(May (10)):708-720.
14. Perry K. From mouse to man: the early clinical testings. Drug Information Journal 1997, 31:729-736.
15. Storer B., DeMets D. Current phase I/II designs: are they adequate?. Journal of Clinical Research and Drug Development 1987, 1:121-130.
16. Simon R., Freidlin B., Rubinstein L., et al. Accelerated titration designs for phase I clinical trials in oncology. Journal of the National Cancer Institute 1997, 89(August (15)):1138-1147.
17. Penel N., Isambert N., Leblond P., et al. Classical 3+3 design" versus "accelerated titration designs": analysis of 270 phase 1 trials investigating anti-cancer agents. Investigational New Drugs 2009, 27(December (6)):552-556.
18. Ivy S.P., Siu L.L., Garrett-Mayer E., et al. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clinical Cancer Research 2010, 16(March (6)):1726-1736.
19. Ishizuka N., Ohashi Y. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials. Statistics in Medicine 2001, 20(September (17/18)):2661-2681.
20. Paoletti X., Baron B., Schöffski P., et al. Using the continual reassessment method: lessons learned from an EORTC phase I dose finding study. European Journal of Cancer 2006, 42(July (10)):1362-1368.
21. Bailey S., Neuenschwander B., Laird G., et al. A Bayesian case study in oncology Phase I combination dose-finding using logistic regression with covariates. Journal of Biopharmaceutical Statistics 2009, 19(3):469-484.
22. Thall P.F., Cook J.D., Estey E.H. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations. Journal of Biopharmaceutical Statistics 2006, 16(5):623-638.
23. Thall P.F., Cook J.D. Dose-finding based on efficacy-toxicity trade-offs. Biometrics 2004, 60(September (3)):684-693.
24. Ananthakrishnan R., Gona P. Pharmacological modeling and biostatistical analysis of a new drug. Open Access Journal of Clinical Trials 2010, 2(April):59-82.
25. Gabrielsson J., Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications 2007, fourth ed.
26. Piantadosi S., Liu G. Improved designs for dose escalation studies using pharmacokinetic measurements. Statistics in Medicine 1996, 15(August (15)):1605-1618.
27. Rubinstein L., Crowley J., Ivy P., et al. Randomized phase II designs. Clinical Cancer Research 2009, 15(March (6)):1883-1890. [Epub Review 2009 March 10].
28. London W.B., Chang M.N. One- and two-stage designs for stratified phase II clinical trials. Statistics in Medicine 2005, 24(September (17)):2597-2611.
29. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989, 10(March (1)):1-10.
30. Bryant J., Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 1995, 51(December (4)):1372-1383.
31. Mandrekar S.J., Sargent D.J. Clinical trial designs for predictive biomarker validation: one size does not fit all. Journal of Biopharmaceutical Statistics 2009, 19(3):530-542.
32. Wang S.J., Hung H.M., O'Neill R.T. Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal 2009, 51(April (2)):358-374.
33. Jenkins M., Stone A., Jennison C. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 2011, 10(July-August (4)):347-356.
34. McShane L.M., Hunsberger S., Adjei A.A. Effective incorporation of biomarkers into phase II trials. Clinical Cancer Research 2009, 15(March (6)):1898-1905. [Review].
35. Ananthakrishnan R., Menon S. Integration of cell biology, pharmacological modeling and statistical analysis. Part I. Cell biology and PK/PD in the oncology paradigm. Critical Reviews in Oncology/Hematology 2012, 83(August (2)):153-169.
36. Chow S.C., Chang M. Adaptive design methods in clinical trials - a review. Orphanet Journal of Rare Diseases 2008, 3(May):11. [Review].
37. Tsuchida Y., Therasse P. Response evaluation criteria in solid tumors (RECIST): new guidelines. Medical and Pediatric Oncology 2001, 37(July (1)):1-3.
38. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009, 45(January (2)):228-247.
39. O'Brien P.C., Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 1979, 35(September (3)):549-556.
40. Pocock S.J., Hughes M.D. Practical problems in interim analyses, with particular regard to estimation. Controlled Clinical Trials 1989, 10(December (Suppl. 4)):209S-221S.
41. Hughes M.D., Pocock S.J. Stopping rules and estimation problems in clinical trials. Statistics in Medicine 1988, 7(December (12)):1231-1242.
42. Geller N.L., Pocock S.J. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics 1987, 43(March (1)):213-223.